PFizer Malaysia has announced that the 20-Valent conjugate pneumococcal vaccine (PCV20) has been approved by the Ministry of Health (MOH) to be used among individuals at age as early as age 6 weeks and under 18 yearsand adults 18 years and up throughout Malaysia. PCV20 offers a more comprehensive conjunction pneumococcal vaccine in Malaysia, with protection against 20 Serotaip Streptococcus pneumoniaewhich is a bacterium that causes significant diseases such as pneumonia, meningitis, sepsis and middle ear infections, ⁴.
This announcement was made at the right time because Malaysia still faced a high burden on pneumococcal disease, especially between two main population groups: children and senior citizens. In addition, pneumococci is one of the main causes of various invasive infections at all ages, including invasive pneumonia. According to the Malaysian Ministry of Health, Pneumonia is the main cause of national death, which has grown more 18,000 lives in the year of 2023⁶. The risk of infection increases significantly among senior citizens and individuals with non-communicable diseases (NCD) such as diabetes, heart disease and chronic lung disease.
“This agreement is an important achievement in the prevention of diseases in Malaysia,” said Mrs. Deborah Seifert, Head of Clusters for Malaysia, Indonesia, Singapore and the Philippines in Pfizer. “PCV20 strengthens our commitment to support a healthier community by helping to protect more people, in more life stages, than potential infections.
Public Health Priorities: More comprehensive protection is needed
Malaysian demographic profile shows rapid development. In the year of 2030, 1 of 5 Malaysians are expected to age 60 years and over⁹. At the same time, the prevalence of NCD continues to increase, with 1 of 6 Adults have diabetes and 1 of 3 Hypertension or cholesterol levels high ¹¹. Chronic diseases such as heart failure and chronic kidney disease also show an increase. This condition weakens the immune system and increases vulnerability to respiratory infections such as pneumonia pneumococci.
“Pneumococcal disease is often not identified until late. As long as I take care of patients, I see many seniors in Malaysia being treated in hospitals because of pneumonia complications; some need intensive care, and some take a long time to recover. In fact, pneumonia is the main cause is not an isolated case, but a pattern that can be prevented.
PCV20 was developed based on PCV13, with the addition of protection against Seven additional serotypes – 8, 10A, 11A, 12F, 15B, 22F and 33F – related to antibiotic resistance and invasive disease.
Comprehensive protection for children in Malaysia
Dynamic pneumococcal serotype is the main challenge in controlling pneumococcal disease. PCV20 is formulated to overcome this gap, with a broader scope of serotypes in response to the growth of disease patterns, ¹⁵.
“Every parent certainly wants to give their children a good start, and as a pediatric specialist, we see the importance of the early years of life for life,” Prof. Datuk Dr. Zulkifli Ismail, a pediatric consultant and a child listener.
“The child’s immune system is still developing in the early years, and this is the time for them to be the most exposed to serious infections such as meningitis or sepsis pneumococci that can have long-term effects, ¹⁸”. “
Based on Pfizer Legacy: PCV7 → PCV13 → PCV20
Pfizer introduced the first conjugate pneumococcal vaccine, PCV7, for more than two decades, followed by PCV13¹⁹. Both vaccines have been widely used globally and are included in the public immune program ² ²¹. PCV20 is the next evolution, which is designed to describe changes in disease and the current population of the current needs, ¹⁵.
“In recent years, we have seen a global increase in non-PCV13 serotypes. Serotype 8 has now appeared as one of the main causes of invasive pneumococcal disease in children and adults, and this trend has continued for the past few years,” said Prof. Dr. Mark van der Linden, Director, National Reference Center for Streptoccal, Germany, Germany. “Changes in this epidemiological pattern further strengthen the importance of higher Valen vaccines such as PCV20, which helps cover critical protection gaps and reflect the latest scientific understanding¹, ¹⁵, ²².”
“In an effort to strengthen the adult immunity landscape in Malaysia, public education and a awareness campaign of sustainable disease will play an important role,” Prof. Dr. Zamberi Sekawi, President of Malaysian Infectious Disease and Chemotherapy Community. “Now with the availability of PCV20, we need to strengthen our efforts to strengthen the immunization of adults in this country. Health professionals are the main message in encouraging more adults to seek immunizations. With the support of medical organizations, policy makers and the media, we can build a healthier and more protected country.”
PCV20 has been approved above 40 countriesIncluding the United States, Britain, Hong Kong and Singapore, ²⁴, ²⁵, ²⁶. Approval in Malaysia is supported by comprehensive data from clinical studies involving adult and child populations, which shows an immune response to PCV13 to 13 Serotaip origin and additional immunogenicity for 7 Serotaip just entered. This vaccine also shows a consistent level of tolerance in various age groups, including when given with other routine vaccines.
Malaysian Pfizer General PCV20 PCV20 Vaccine Approval for Children and Adults Appears the first time in Siakap Keli.
Game Center
Game News
Review Film
Rumus Matematika
Anime Batch
Berita Terkini
Berita Terkini
Berita Terkini
Berita Terkini
review anime
